Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28014894 | 0.90 | NCF1 (0.53) | KDM4ENCF1ACHEMCHR1ALDH1A1 | |
| SCHEMBL23044015 | 0.89 | TLR8 (0.52) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL28521004 | 0.87 | TLR8 (0.53) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL28514975 | 0.87 | TLR8 (0.53) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL9709703 | 0.86 | NCF1 (0.59) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL8912375 | 0.86 | ACHE (0.58) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL8907365 | 0.86 | ACHE (0.58) | KDM4ENCF1ACHEMCHR1ALDH1A1 | |
| SCHEMBL8907361 | 0.84 | ACHE (0.56) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL8908598 | 0.84 | ACHE (0.56) | KDM4ENCF1ACHEALDH1A1HPGD | |
| SCHEMBL8907350 | 0.84 | ACHE (0.56) | KDM4ENCF1ACHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065166-A1 | Bone Modulators And Methods Therewith | ESPINA VIRGINIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | DICKSON JR JOHN K | 2009-03-12 | — | — | US | disclosed |
| US-7452887-B2 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AMPHORA DISCOVERY CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AGRIUS GROUP, LLC. | 2006-01-12 | — | — | US | disclosed |
| US-5182275-A | Intermediates for memory enhancers | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-01-26 | — | — | US | disclosed |
| WO-1992022533-A1 | 4-AMINOQUINOLINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |
| US-4942168-A | INTERMEDIATES FOR 1,2-DIHYDRO-3-METHYL-3H-1,4-OXAZINO 2,3-C!QU INOLINE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0299345-A2 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | ATP5ME, ABCG2, ATP5MG | KDM4E 3248/4885NCF1 672/4885ACHE 31/4885 |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | KDM4E 3040/4885NCF1 2180/4885ACHE 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.